![Ben Harshbarger](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Ben Harshbarger
General Counsel at
XILIO THERAPEUTICS, INC.
Profile
Benjamin J.
Harshbarger is Chief Legal Officer at Xilio Therapeutics, Inc. since 2026.
Formerly, Mr. Harshbarger was Chief Legal Officer at Astria Therapeutics, Inc. from 2021 to 2026, Chief Executive Officer & General Counsel at Novelion Therapeutics, Inc. from 2018 to 2019, General Counsel at Aegerion Pharmaceuticals, Inc. from 2015 to 2016, Senior Director-Corporate Counsel at Cubist Pharmaceuticals LLC from 2008 to 2012, Senior Director-Deputy General Counsel at ViaCell, Inc. from 2006 to 2008, Associate General Counsel at Biogen, Inc. from 2001 to 2006, Associate at Mintz, Levin, Cohn, Ferris, Glovsky & Popeo PC from 1996 to 2001.
Education includes undergraduate studies at the University of Richmond and graduate studies at Boston College Law School.
Ben Harshbarger active positions
| Companies | Position | Start |
|---|---|---|
| XILIO THERAPEUTICS, INC. | General Counsel | 2026-06-28 |
Former positions of Ben Harshbarger
| Companies | Position | End |
|---|---|---|
| ASTRIA THERAPEUTICS, INC. | General Counsel | 2026-01-22 |
| NOVELION THERAPEUTICS INC. | Chief Executive Officer | 2019-12-30 |
| AEGERION PHARMACEUTICALS, INC. | General Counsel | 2016-06-30 |
| CUBIST PHARMACEUTICALS INC | General Counsel | 2012-02-29 |
ViaCell, Inc.
 ViaCell, Inc. Medical SpecialtiesHealth Technology Provides and develops cellular medicine for the treatment of diseases | Corporate Officer/Principal | 2008-02-29 |
Training of Ben Harshbarger
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
63
1st degree connections
10
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 10 |
|---|---|
Biogen, Inc.
 Biogen, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets therapies for neurological and neurodegenerative diseases | Health Technology |
Cubist Pharmaceuticals LLC
 Cubist Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Engages in research, development and commercialization of pharmaceutical products | Health Technology |
ViaCell, Inc.
ViaCell, Inc. Medical SpecialtiesHealth Technology Provides and develops cellular medicine for the treatment of diseases | Health Technology |
Aegerion Pharmaceuticals, Inc.
 Aegerion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops and commercializes therapies for hyperlipidemia and metabolic diseases | Health Technology |
Astria Therapeutics, Inc.
 Astria Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Discovers, develops and commercializes novel therapeutics for rare and niche allergic & immunological diseases | Health Technology |
Mintz, Levin, Cohn, Ferris, Glovsky & Popeo PC
 Mintz, Levin, Cohn, Ferris, Glovsky & Popeo PC Miscellaneous Commercial ServicesCommercial Services Provides legal services | Commercial Services |
University of Richmond
 University of Richmond Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Boston College Law School
 Boston College Law School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Xilio Therapeutics, Inc.
 Xilio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company which develops tumor-selective immuno-oncology therapies | Health Technology |
Novelion Therapeutics, Inc.
 Novelion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets rare disease products, metreleptin and lomitapide | Health Technology |
- Stock Market
- Insiders
- Ben Harshbarger
Choose MarketScreener 
